Laboratorio de Genética Molecular Humana, Facultad de Medicina/Centro Regional de Investigaciones Biomédicas, Universidad de Castilla-La Mancha, Avda. de Almansa, no. 14, 02006, Albacete, Spain.
Clin Genet. 2010 Jan;77(1):70-8. doi: 10.1111/j.1399-0004.2009.01284.x. Epub 2009 Sep 29.
Glaucoma is an inherited complex and heterogeneous disease, and one of the most prevalent causes of definitive blindness in the world. Recent reports have indicated that heterozygous mutations of the CYTOCHOROME P4501B1 (CYP1B1) gene are present in 4-10% of patients with primary open-angle glaucoma (POAG). To further evaluate the role of CYP1B1 mutations in POAG we extended our previous association study and carried out a functional analysis of the mutations identified by polymerase chain reaction (PCR) DNA sequencing of the three exons of the gene in a total of 245 unrelated Spanish patients and 326 control subjects. Eight of nine different mutations identified in these patients were cloned and functionally assessed by measuring ethoxyresorufin O-deethylation activity and CYP1B1 stability in transiently transfected HEK-293T cells. All these mutants showed reduced catalytic activity, ranging from 20% to 60% of wild-type and/or decreased protein stability and, therefore, they were classified as hypomorphic alleles. No null alleles were identified in these patients. We found heterozygous hypomorphic CYP1B1 mutations in 17 (6.7%) patients and in seven controls (2.1%) showing that these mutations are associated with an increased risk of POAG (p = 0.005; odds ratio = 3.2; 95% confidence interval = 1.30-9.19). Our data suggest that hypomorphic CYP1B1 mutations are, to date, the main known genetic risk factor in POAG.
青光眼是一种遗传性复杂且异质性疾病,是世界上导致终末期失明的最常见原因之一。最近的报告表明,细胞色素 P4501B1(CYP1B1)基因的杂合突变存在于 4-10%的原发性开角型青光眼(POAG)患者中。为了进一步评估 CYP1B1 突变在 POAG 中的作用,我们扩展了之前的关联研究,并对通过基因的三个外显子的聚合酶链反应(PCR)DNA 测序鉴定的突变进行了功能分析,共涉及 245 名无关的西班牙患者和 326 名对照。在这些患者中鉴定出的 9 种不同突变中的 8 种被克隆,并通过测量瞬时转染的 HEK-293T 细胞中的乙氧基 RESORUFIN O-脱乙基化活性和 CYP1B1 稳定性来进行功能评估。所有这些突变体显示出降低的催化活性,范围从野生型的 20%到 60%和/或降低的蛋白质稳定性,因此它们被归类为低功能等位基因。在这些患者中未鉴定出无效等位基因。我们在 17 名(6.7%)患者和 7 名对照(2.1%)中发现了杂合低功能 CYP1B1 突变,表明这些突变与 POAG 的风险增加相关(p = 0.005;比值比 = 3.2;95%置信区间 = 1.30-9.19)。我们的数据表明,低功能 CYP1B1 突变是迄今为止 POAG 的主要已知遗传风险因素。